J. Goldman & Co’s Structure Therapeutics GPCR Stock Holding History

J. Goldman & Co’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,500	Closed	-$530K	–	513
2024 Q2	$530K	Sell	13,500 -6,800	-33%	-$279K	0.02%	356
2024 Q1	$870K	Buy	+20,300	New	+$856K	0.03%	280

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

J. Goldman & Co's GPCR Position: Q1 2026 in Review

J. Goldman & Co sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 13,601 shares — an estimated $946K sold.

J. Goldman & Co first reported a position in GPCR in Q4 2024 and held it in 2 quarters. The position peaked at $946K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

J. Goldman & Co reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 13,601 Structure Therapeutics shares in Q1 2026, an estimated $946K.
J. Goldman & Co first reported a position in Structure Therapeutics in Q4 2024 and held it in 2 quarters.
J. Goldman & Co's Structure Therapeutics position peaked at $946K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.